UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934.
Date of Report August 1, 1994
Commission File Number 1-5910
CARTER-WALLACE, INC.
(Exact name of registrant as specified in its charter)
Delaware 13-4986583
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
1345 Avenue of the Americas, New York, NY 10105
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 212-339-5000
<PAGE>
<PAGE>
Item 5 - Other Events
Carter-Wallace, Inc. announced on August 1, 1994 that it had sent
a letter to approximately 240,000 physicians recommending, in
conjunction with the Federal Food and Drug Administration, the
immediate withdrawal of patients from treatment with Felbatol
(felbamate), unless, in the physician's judgment, an abrupt
withdrawal would be deemed to pose a more serious risk to the
patient. Patients on Felbatol are advised to consult their
physicians and not to discontinue the use of Felbatol on their
own.
Carter-Wallace's recommendation was prompted by ten cases (nine
domestic and one foreign) of aplastic anemia in association with
the use of Felbatol. No such cases were observed during the
premarketing, clinical testing and development of Felbatol.
Carter-Wallace introduced Felbatol in September of 1993 for the
treatment of partial seizures with and without secondary
generalization in adults and for Lennox-Gastaut Syndrome, a
serious form of childhood epilepsy.
- 1 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
Carter-Wallace, Inc.
(Registrant)
DATED: August 1, 1994 BY: s/Ralph Levine
Ralph Levine
Vice President,
Secretary and
General Counsel
- 2 -
